Clinical Trial Update: A Study of BL-M07D1 With or Without Pertuzumab Versus Taxane + Trastuzumab and Pertuzumab in Neoadjuvant Therapy for HER2-Positive Breast Cancer [Phase 2, Phase 3]

View source ↗

Summary

A neoadjuvant phase 2/3 trial in HER2-positive breast cancer evaluating BL-M07D1 with or without pertuzumab versus a taxane plus trastuzumab and pertuzumab; the…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• BL-M07D1
• HERCEPTIN (trastuzumab)
• Perjeta (pertuzumab)
• Taxane (unspecified) (taxane)

Snippet

Sponsor: Sichuan Baili Pharmaceutical Co., Ltd. | Conditions: HER2-positive Breast Cancer | Phase 2, Phase 3 | Status: RECRUITING